Usefulness of GATA3 and p40 Immunostains in the Diagnosis of Metastatic Urothelial Carcinoma in Cytology Specimens

被引:10
作者
Brandler, Tamar C. [1 ]
Aziz, Mohamed S. [1 ]
Rosen, Lisa M. [2 ]
Bhuiya, Tawfiqul A. [1 ]
Yaskiv, Oksana [1 ]
机构
[1] Hofstra North Shore LIJ Sch Med, Dept Pathol, Lake Success, NY 11042 USA
[2] Hofstra North Shore LIJ Sch Med, Dept Biostat, Lake Success, NY 11042 USA
关键词
GATA3 (GATA-binding protein 3); p40; urothelial carcinoma; cytology; immunocytochemistry; SQUAMOUS-CELL; DELTA-NP63; EXPRESSION; P63; IMMUNOHISTOCHEMISTRY; ADENOCARCINOMA; MARKERS;
D O I
10.1002/cncy.21424
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: GATA3 (GATA-binding protein 3) expression in urothelial carcinoma (UC) and mammary carcinomas has been recently reported. However, to the authors' knowledge, studies examining GATA3 staining of metastatic UC (MUC) in cytology specimens are lacking. Delta Np63 (p40) has been shown to be expressed highly selectively in squamous cell carcinomas (SCCs) but the literature concerning the expression of p40 in UC is limited and controversial. In the current study, the authors evaluated the usefulness of GATA3 and p40 in the diagnosis of MUC in cytology specimens. METHODS: Thirty-two MUC cytology cases and 44 controls (22 UC cases and 22 SCC cases) were stained for GATA3, p40, and p63 and nuclear staining intensity and the percentage of positive cells were recorded and compared. RESULTS: MUC cytology cases stained positive for GATA3, p40, and p63 in 78.13%, 80.65%, and 61.29% of cases, respectively, with moderate/strong staining intensity. MUC cases had a significantly higher percentage of GATA3 positivity compared with SCC controls (P<.001), but GATA3 positivity was not found to be significantly different from UC controls (90.91%) (P=.28). For p40 positivity, there was no significant difference observed between MUC cases, UC controls (95.45%), and SCC controls (90.91%) (P=.29). p63 positivity was found to be significantly lower in MUC cases compared with UC controls (95.45%) and SCC controls (95.45%) (P<.01). CONCLUSIONS: The results of the current study demonstrate that GATA3 is useful in confirming the diagnosis of MUC in cytology specimens and in distinguishing between MUC and SCC. p40 is a valuable adjunct to GATA3 in the diagnosis of MUC in cytology specimens, especially when SCC is not part of the clinical differential diagnosis. (C) 2014 American Cancer Society.
引用
收藏
页码:468 / 473
页数:6
相关论文
共 50 条
[31]   Endosalpingiosis Is Negative for GATA3 A Useful Marker for Distinguishing Metastatic Breast Carcinoma From a Benign Mimicker [J].
White, Marissa J. ;
Vang, Russell ;
Argani, Pedram ;
Cimino-Mathews, Ashley .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2021, 145 (11) :1448-1452
[32]   Evaluation of GATA3 and p53 Expression in Urothelial Carcinoma and their Association with Clinicopathological Parameters: A Cross-sectional Study [J].
Agarwal, Anjali ;
Dasnayak, Goutami ;
Senapati, Urmila ;
Jagdev, Jagat Ballav ;
Raman, Sarojini .
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2024, 18 (09) :EC1-EC6
[33]   GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder*,** [J].
Plage, Henning ;
Samtleben, Henrik ;
Hofbauer, Sebastian ;
Kornienko, Kira ;
Weinberger, Sarah ;
Bruch, Paul Giacomo ;
Elezkurtaj, Sefer ;
Rossner, Florian ;
Schallenberg, Simon ;
Kluth, Martina ;
Lennartz, Maximilian ;
Blessin, Niclas C. ;
Marx, Andreas H. ;
Fisch, Margit ;
Rink, Michael ;
Slojewski, Marcin ;
Kaczmarek, Krystian ;
Ecke, Thorsten ;
Hallmann, Steffen ;
Koch, Stefan ;
Adamini, Nico ;
Minner, Sarah ;
Simon, Ronald ;
Sauter, Guido ;
Klatte, Tobias ;
Schlomm, Thorsten ;
Horst, David ;
Zecha, Henrik .
HUMAN PATHOLOGY, 2022, 130 :10-17
[34]   A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer [J].
Tozbikian, Gary H. ;
Zynger, Debra L. .
HUMAN PATHOLOGY, 2019, 85 :221-227
[35]   Comparative expression of TRPS1, GATA3, SOX10, mammaglobin, and GCDFP-15 in effusion specimens with breast carcinoma [J].
Bradt, Ashley ;
Jing, Xin ;
Smola, Brian S. ;
Lew, Madelyn .
DIAGNOSTIC CYTOPATHOLOGY, 2023, 51 (11) :665-673
[36]   Efficacy of GATA3 Versus BRST2 for the Identification of Metastatic Breast Carcinoma in the Upper GI Tract: Which Performs Better? [J].
Salagean, Diana ;
Streutker, Catherine ;
Faragalla, Hala ;
Jakate, Kiran .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (07) :501-507
[37]   Immunostaining for thyroid transcription factor 1, Napsin A, p40, and cytokeratin 5 aids in differential diagnosis of non-small cell lung carcinoma [J].
Ikeda, Satoshi ;
Naruse, Keishi ;
Nagata, Chigusa ;
Kuramochi, Masami ;
Onuki, Takuya ;
Inagaki, Masaharu ;
Suzuki, Keiko .
ONCOLOGY LETTERS, 2015, 9 (05) :2099-2104
[38]   Differentiating Small Cell Carcinoma From Squamous Cell Carcinoma in Cytologic Specimens: A Head-to-Head Comparison of p40 and p63 Using Cell Block Immunocytochemistry [J].
Gailey, Michael P. ;
Bellizzi, Andrew M. ;
Jensen, Chris S. .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (01) :11-15
[39]   GATA3 AND P63 IMMUNOSTAINING ANALYSIS IN HIGH GRADE BLADDER CARCINOMA [J].
Patriarca, Carlo ;
Cavallero, Alessandra .
ANTICANCER RESEARCH, 2013, 33 (05) :2252-2252
[40]   Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma [J].
Naik, Meenatai ;
Rao, B. Vishal ;
Challa, Sundaram ;
Fonseca, Daphne ;
Sudha, S. Murthy ;
Giridhar, Ashwin ;
Sharma, Rakesh ;
Raju, K. V. V. N. ;
Rao, T. Subramanyesh war .
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) :S149-S159